VJHemOnc is committed to improving our service to you

Myeloma 2018 | Anti-BCMA CAR T-cells in myeloma: what data do we have so far?

VJHemOnc is committed to improving our service to you

Yi Lin

BCMA is an exciting therapeutic target for multiple myeloma (MM). Here, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, discusses current trials of CAR T-cell products that are targeting BCMA, and their data so far. She highlights that the patient population who have received this therapy so far have been heavily pre-treated and have limited therapeutic options. Dr Lin also discusses future strategies to futher improve CAR T-cell therapy. This interview took place at the Myeloma 2018 meeting, held in San Diego, CA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter